- Home
- AMTM vs RYTM Comparison
AMTM vs RYTM Comparison
Compare AMTM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMTM
- RYTM
- Stock Information
- Founded
- AMTM 2020
- RYTM 2008
- Country
- AMTM United States
- RYTM United States
- Employees
- AMTM N/A
- RYTM N/A
- Industry
- AMTM
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AMTM
- RYTM Health Care
- Exchange
- AMTM NYSE
- RYTM Nasdaq
- Market Cap
- AMTM 5.6B
- RYTM 5.9B
- IPO Year
- AMTM N/A
- RYTM 2017
- Fundamental
- Price
- AMTM $25.60
- RYTM $86.45
- Analyst Decision
- AMTM Buy
- RYTM Strong Buy
- Analyst Count
- AMTM 6
- RYTM 13
- Target Price
- AMTM $26.50
- RYTM $89.77
- AVG Volume (30 Days)
- AMTM 1.5M
- RYTM 1.0M
- Earning Date
- AMTM 08-05-2025
- RYTM 08-05-2025
- Dividend Yield
- AMTM N/A
- RYTM N/A
- EPS Growth
- AMTM N/A
- RYTM N/A
- EPS
- AMTM 0.10
- RYTM N/A
- Revenue
- AMTM $11,261,000,000.00
- RYTM $136,863,000.00
- Revenue This Year
- AMTM $70.66
- RYTM $37.47
- Revenue Next Year
- AMTM $2.26
- RYTM $71.16
- P/E Ratio
- AMTM $267.90
- RYTM N/A
- Revenue Growth
- AMTM 38.56
- RYTM 48.88
- 52 Week Low
- AMTM $16.01
- RYTM $40.61
- 52 Week High
- AMTM $34.50
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- AMTM N/A
- RYTM 66.82
- Support Level
- AMTM N/A
- RYTM $86.25
- Resistance Level
- AMTM N/A
- RYTM $92.14
- Average True Range (ATR)
- AMTM 0.00
- RYTM 3.68
- MACD
- AMTM 0.00
- RYTM -0.14
- Stochastic Oscillator
- AMTM 0.00
- RYTM 72.31
About AMTM AMENTUM HOLDINGS INC
Amentum Holdings Inc is engaged in engineering and technology solutions. The United States and its allies trust it to address their technical and complex scientific, security, and sustainability challenges.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.